Get the Stockscreener App
0.9737
4.82%
0.0448
Biocardia Inc stock is traded at $0.9737, with a volume of 158.15K.
It is up +4.82% in the last 24 hours and up +21.41% over the past month.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
See More
Previous Close:
$0.9289
Open:
$0.95
24h Volume:
158.15K
Relative Volume:
0.06
Market Cap:
$14.49M
Revenue:
$3,000
Net Income/Loss:
$-7.78M
P/E Ratio:
-0.9411
EPS:
-1.0346
Net Cash Flow:
$-7.49M
1W Performance:
-0.47%
1M Performance:
+21.41%
6M Performance:
-14.59%
1Y Performance:
-48.48%
1-Day Range:
$0.9103
$0.98
1-Week Range:
$0.8521
$0.987
52-Week Range:
$0.75
$2.29
Biocardia Inc Stock (BCDA) Company Profile
Name
Biocardia Inc
Sector
Industry
Phone
650-226-0123
Address
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA vs MOBBW, PSNYW, GOODO, SHMD, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
1.86 | 2.83B | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.89 | 388.34M | 2.07B | -1.42B | -1.37B | -0.6765 |
GOODO
Gladstone Commercial Corporation
|
20.88 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
5.45 | 348.74M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
48.03 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-21 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Stock (BCDA) Latest News
BioCardia CEO Peter Altman buys $1,748 in company stock - Investing.com
BioCardia CEO Peter Altman buys $1,748 in company stock By Investing.com - Investing.com India
BioCardia (BCDA) CEO Peter Altman purchases 1,900 shares at $0.92 average price - Stock Titan
BioCardia (BCDA) Advances Regulatory Pathway, Faces High Price-t - GuruFocus
BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan and US ... - Yahoo! Finance Canada
BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulat - GuruFocus
BioCardia, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
BioCardia Q2 loss narrows 67.5% YoY; regulatory milestones advance - scanx.trade
BCDA: Regulatory milestones and strong cash position support major market entry for cardiac therapies - TradingView
Earnings call transcript: BioCardia posts q2 2026 loss beat, shares rise after hours - Investing.com
Is BioCardia Inc (BCDA) Facing Financial Challenges After Q2 Ear - GuruFocus
BioCardia reports Q2 2026 net loss narrows to $1.6M; cash $4.1M with runway into 2027 - TradingView
BioCardia Reports Q2 2026 Net Loss of $1.6 Million - Quiver Quantitative
Q2 2026 BioCardia Inc Earnings Call Transcript - GuruFocus
BCDA: Regulatory progress, clinical advances, and improved financials position for late 2026 submissions - TradingView
BioCardia, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results - The Manila Times
BRIEF-BioCardia, Inc. Q2 Net Income USD -1.613 Million - TradingView
BioCardia (BCDA.US) will release its earnings report before market open on August 12. - Moomoo
BioCardia Inc (BCDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
BioCardia, Inc. Revenue Breakdown – NASDAQ:BCDA - TradingView
BioCardia Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
BioCardia Inc (BCDA) Stock News Today - tradingkey.com
Insiders In BioCardia Still Down 21% On US$1.08m Investment - simplywall.st
BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026 - The Manila Times
BioCardia to Report Second Quarter 2026 Financial Results and Provide Corporate Update on August 12 Conference Call - Quiver Quantitative
BioCardia Sets Live Webcast for Q2 Results on Aug. 12 - Stock Titan
BCDA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
BioCardia to report Q2 2026 financial results a... - pluang.com
BioCardia (BCDA) Q1 2026 Earnings: Wider EPS Loss of $0.21 Misses Estimates, Yet Stock Climbs 5.04%Earnings Outlook Update - dars.gov.et
BioCardia Inc. (BCDA) Q1 2026 Earnings: EPS Miss Magnifies Loss Amid Pre-Revenue StageCEO Earnings Statement - dars.gov.et
BioCardia CEO Peter Altman buys $3,900 in common stock By Investing.com - Investing.com Nigeria
Form 4 Biocardia Inc For: 29 July By Investing.com - Investing.com Nigeria
BioCardia CEO Peter Altman buys $3,900 in common stock - Investing.com
BioCardia Inc (BCDA) Valuation: PE, PB & Fair Value Analysis - TradingKey
What date does BioCardia's (BCDA) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
BioCardia Inc (BCDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BCDA|BioCardia Inc|Price:0.824|Chg%:+0.053 - TradingKey
BioCardia Inc (BCDA) Cash Flow - TradingKey
TradingKey - TradingKey
BioCardia Inc (BCDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioCardia Inc (BCDA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioCardia Inc (BCDA) Institutional Confidence - TradingKey
BioCardia Inc (BCDA) Balance Sheet - TradingKey
BCDA|BioCardia Inc|Price:0.850|Chg%:-0.055 - TradingKey
BioCardia, Inc. Revenue Breakdown – FWB:6JU0 - TradingView
BioCardia Inc. (BCDA) Q1 2026 Earnings: EPS Misses Estimates with No Reported RevenueEPS Consistency Score - dars.gov.et
BioCardia (BCDA) CEO Peter Altman purchases 500 shares in July 17 trade - Stock Titan
BioCardia (BCDA) Slips 3.4% as Stock Tests Key Support Near $0.79Zero Gamma Level - dars.gov.et
Form 4 Biocardia Inc For: 15 July By Investing.com - Investing.com Canada
BioCardia CEO Peter Altman buys $3,754 in company stock - Investing.com
Biocardia Inc Stock (BCDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biocardia Inc Stock (BCDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Altman Peter | President and CEO |
Jul 29 '26 |
Buy |
0.78 |
5,000 |
3,900 |
373,885 |
| Altman Peter | President and CEO |
Jul 17 '26 |
Buy |
0.83 |
500 |
415 |
368,885 |
| Altman Peter | President and CEO |
Jul 14 '26 |
Buy |
0.88 |
2,800 |
2,464 |
366,885 |
| Altman Peter | President and CEO |
Jul 15 '26 |
Buy |
0.86 |
1,500 |
1,290 |
368,385 |
| Altman Peter | President and CEO |
Jul 08 '26 |
Buy |
0.97 |
5,500 |
5,335 |
367,485 |
| Altman Peter | President and CEO |
Jul 10 '26 |
Buy |
0.94 |
1,000 |
940 |
369,485 |
| Altman Peter | President and CEO |
Jul 09 '26 |
Buy |
0.90 |
1,000 |
900 |
368,485 |
| Altman Peter | President and CEO |
Jul 08 '26 |
Buy |
0.96 |
5,400 |
5,208 |
361,985 |
| STERTZER SIMON H | Director |
Jun 22 '26 |
Buy |
0.92 |
70,200 |
64,584 |
127,338 |
| STERTZER SIMON H | Director |
Jun 23 '26 |
Buy |
1.00 |
39,000 |
39,000 |
166,338 |
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):